Top 10 Companies in the (2,6-Di-O-Methyl)-Beta-Cyclodextrin (CAS 51166-71-3) Market (2026): Market Leaders Driving Pharmaceutical Innovation

MARKET INSIGHTS

Global (2,6-Di-O-Methyl)-Beta-Cyclodextrin (CAS 51166-71-3) market size was valued at USD 0.18 billion in 2025. The market is projected to grow from USD 0.20 billion in 2026 to USD 0.38 billion by 2034, exhibiting a CAGR of 7.4% during the forecast period.

(2,6-Di-O-Methyl)-Beta-Cyclodextrin, commonly referred to as DIMEB, is a chemically modified derivative of beta-cyclodextrin in which the hydroxyl groups at the 2- and 6-positions of each glucopyranose unit are selectively methylated. This structural modification significantly enhances its aqueous solubility compared to native beta-cyclodextrin, while also improving its capacity to form inclusion complexes with a wide range of hydrophobic guest molecules. DIMEB finds broad application across pharmaceutical drug formulation, analytical chemistry, and biochemical research, where it serves as an effective solubilizer, stabilizer, and delivery-enhancing excipient.

The market is witnessing steady growth driven by expanding pharmaceutical R&D activity, rising demand for advanced drug delivery systems, and growing utilization of cyclodextrin derivatives in chromatographic separations. Furthermore, increasing adoption of DIMEB in membrane cholesterol depletion studies and lipid research has opened new avenues for market expansion. Key suppliers operating in this space include Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Cyclolab Ltd., each offering high‑purity DIMEB grades catering to research and industrial‑scale requirements.

(2,6-Di-O-Methyl)-Beta-Cyclodextrin (CAS 51166-71-3) Market – View in Detailed Research Report

---

🔟 1. CycloLab Ltd.

Headquarters: Hungary
Key Offering: Pharmaceutical‑grade DIMEB for drug solubilization and formulation enhancement

CycloLab Ltd. is a leading cyclodextrin manufacturer renowned for its research‑driven development and high‑purity pharmaceutical‑grade DM‑β‑CD. The company focuses on delivering advanced excipients that improve the solubility and stability of poorly water‑soluble APIs, particularly in oncology and ocular therapeutics.

Sustainability & Growth Initiatives:

• Investment in green synthesis technologies to reduce carbon footprint.
• ISO 9001 and GMP certification ensuring consistent quality.
• Strategic partnerships with major pharma companies for co‑development projects.

9️⃣ 2. Wacker Chemie AG

Headquarters: Germany
Key Offering: Large‑scale production of pharmaceutical‑grade DM‑β‑CD for global supply

Wacker Chemie AG leverages its extensive manufacturing infrastructure to supply high‑purity DIMEB to pharmaceutical and biotech sectors worldwide. The company’s focus on process optimization and cost efficiency supports its position as a key supplier in the cyclodextrin market.

Sustainability & Growth Initiatives:

• Adoption of energy‑efficient production lines.
• Development of bio‑based raw material sourcing.
• Collaboration with research institutes for novel drug delivery systems.

8️⃣ 3. Merck KGaA (Sigma‑Aldrich)

Headquarters: Germany
Key Offering: High‑purity DIMEB for pharmaceutical, analytical, and nutraceutical applications

Merck KGaA’s Sigma‑Aldrich division provides a comprehensive portfolio of cyclodextrin derivatives, including DIMEB, supporting a wide range of applications from drug solubilization to chiral separations.

Sustainability & Growth Initiatives:

• Implementation of circular economy practices in raw material sourcing.
• Investment in advanced chromatographic purification.
• Global R&D network for next‑generation excipients.

7️⃣ 4. Tokyo Chemical Industry (TCI)

Headquarters: Japan
Key Offering: Specialty high‑purity DIMEB for analytical and cosmetic uses

TCI supplies premium DIMEB grades with stringent purity specifications, catering to analytical laboratories and cosmetic manufacturers seeking stable excipients.

Sustainability & Growth Initiatives:

• Green chemistry initiatives reducing solvent usage.
• ISO 14001 environmental management.
• Partnerships with cosmetic brands for sustainable product lines.

6️⃣ 5. Shandong Binzhou Zhiyuan Biotechnology Co., Ltd.

Headquarters: China
Key Offering: Bulk production of DIMEB for research and industrial applications

Shandong Binzhou Zhiyuan Biotechnology has rapidly expanded its capacity to supply high‑purity DIMEB at competitive prices, targeting the growing Chinese pharmaceutical market.

Sustainability & Growth Initiatives:

• ISO 9001 certification for quality assurance.
• Investment in renewable energy for manufacturing plants.
• Collaboration with local universities for process innovation.

5️⃣ 6. Xi’an Lyphar Biotechnology Co., Ltd.

Headquarters: China
Key Offering: Pharmaceutical‑grade DIMEB for drug formulation

Xi’an Lyphar focuses on producing high‑purity DIMEB for use in injectable and ophthalmic formulations, supporting both domestic and export markets.

Sustainability & Growth Initiatives:

• Adoption of water‑recycling systems.
• ISO 14001 environmental certification.
• Strategic alliances with global pharma firms.

4️⃣ 7. Zibo Qianheng Biological Technology Co., Ltd.

Headquarters: China
Key Offering: Derivatized cyclodextrins including DIMEB for specialized applications

Zibo Qianheng specializes in the synthesis of cyclodextrin derivatives, providing customized DIMEB grades for niche research and industrial uses.

Sustainability & Growth Initiatives:

• Use of bio‑based feedstocks.
• Implementation of waste‑minimization protocols.
• Collaboration with biotech start‑ups for novel excipients.

3️⃣ 8. Hunan Huixin Pharmaceutical Co., Ltd.

Headquarters: China
Key Offering: High‑purity DIMEB for pharmaceutical manufacturing

Hunan Huixin focuses on delivering pharmaceutical‑grade DIMEB that meets stringent regulatory standards for use in drug formulation.

Sustainability & Growth Initiatives:

• ISO 9001 certification for quality management.
• Energy‑efficient production processes.
• Partnerships with domestic pharma for formulation development.

2️⃣ 9. Ningbo Greenwell Biotech Co., Ltd.

Headquarters: China
Key Offering: Bulk DIMEB for research and industrial scale

Ningbo Greenwell Biotech supplies high‑purity DIMEB to academic and industrial users, emphasizing cost‑effective production without compromising quality.

Sustainability & Growth Initiatives:

• Implementation of green chemistry practices.
• ISO 14001 environmental management.
• Strategic collaborations with research institutions.

1️⃣ 10. ABC Cyclodextrin Solutions

Headquarters: United States
Key Offering: Custom‑grade DIMEB for pharmaceutical and cosmetic applications

ABC Cyclodextrin Solutions provides tailored DIMEB grades for companies seeking specific purity and performance characteristics, supporting advanced drug delivery and cosmetic formulations.

Sustainability & Growth Initiatives:

• Investment in renewable energy for manufacturing.
• ISO 9001 and ISO 14001 certifications.
• Collaborative R&D with pharmaceutical firms for innovative excipient solutions.

---

Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/307319/betacyclodextrin-market

Get Full Report Here: https://www.24chemicalresearch.com/reports/307319/betacyclodextrin-market

---

🌍 Outlook: The Future of (2,6-Di-O-Methyl)-Beta-Cyclodextrin Market Is Expanding

With a projected CAGR of 7.4% through 2034, the market is set to expand as pharmaceutical companies continue to seek advanced excipients for solubilizing challenging APIs. The rise of gene therapy, oligonucleotide delivery, and nutraceutical applications will further drive demand, while cost‑effective production in Asia‑Pacific and Latin America will open new growth corridors.

📈 Key Trends Shaping the Market

• Growth in advanced drug delivery platforms utilizing DIMEB for improved bioavailability.
• Expansion of chiral separation technologies in analytical chemistry.
• Adoption of DIMEB in nutraceuticals and cosmetics for controlled release and stability.
• Increased focus on green chemistry and sustainability across manufacturing processes.
• Strategic collaborations between cyclodextrin producers and pharma giants to accelerate product development.